Go to Page # Page of 21

The Role of Panitumumab on Redox Status of Colon Cancer Cell Lines

 E. Giannopoulou, K Floratou and H.P. Kalofonos
Description: The FDA granted approval to panitumumab for the treatment of patients with EGFR-expressing, metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine-, oxaliplatin-, & irrinotecan- containing chemotherapy regimens. Panitumumab is a human IgG2 monoclonal antibody that binds to EGFR and inhibits its phosphorylation & therefore its signaling pathway activation. Colorectal cancer is the 4th most prevalent carcinoma in Western society and the 2nd cause of cancer death.
Views: 2239
Domain: Medical
Category: Biotech/Pharma
weSRCH App on Apple
The possible role of panitumumab on redox status of colon cancer cell lines DLD-1 and HT-29
E. Giannopoulou, K Floratou and H.P. Kalofonos

Clinical Oncology Laboratory, Division of Oncology, Department of Medicine, University of Patras, Patras, Rio, 26504

�On September 27, 2006, the FDA granted approval to
panitumumab (VectibixTM, Amgen, Inc., Thousand Oaks, CA) for the treatment of ... See more

Recent Presentations

19 April, 2019

FDA Approach to the Opioids Crisis

Opioid Crisis is not one crisis, but multiple challenges to prescribers, patients & healthcare system. FDA is working in a prioritized way in multiple areas to confront opioid over

18 April, 2019
Ralph F. Hall
17 April, 2019